The product, Sofpulse, is a viable product. The CEO, Alan Collier only acquired the product to self enrich himself. He does not care about shareholders. He will not communicate with the shareholders. Below is a list of PRs and their end results.
Aside from the below PRs, many PRs were made about distribution agreements and partnerships. Nothing ever developed from those PRs. Sales have not increased.
June 21, 2020 - Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
FALSE. Dilution is still existant and eroding shareholder value.
March 25, 2020 - Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
They must still be seeking. No news update.
February 20, 2020 - Endonovo Therapeutics Begins Process For Medical Reimbursements
Begins is a very loose word. Could mean reading about it. No further action nor news has been released about this.
February 4, 2020 - Endonovo Therapeutics Reduces Debt
This was just moving preferred shares and then converting it to common shares and dumping into the float.
December 19, 2020 - Endonovo Therapeutics Announces Effective Date of Previously Announced Reverse Split of Common Stock
This split eroded all shareholder value due to continued dilution afterwards. Company said they would never reverse split and not only performed one, did a very large one: 1000 to 1.
September 30, 2019 - Endonovo Therapeutics Appoints Dr. William Li as Strategic Advisor to the CEO
No further news came after this. Was probably paid for the use of his name only for the P.R.
Early 2019 - Hires VP of Sales and a Chief Medical Office. These positions are later eliminated with no PR. Just swept under the rug.
Early 2019 - Initiates a patent lawsuit against 2 companies. Both lawsuits were lost.
Early 2019 Shareholder letter -
- Signing two marketing agreements with well established medical device sales organizations - (Nothing came from this. Sales has been dismal then and continue to be just as bad).
Establishment and expansion of a rapidly growing sales department (Salespeople were hired, but sales never reached the level promised in a published PR).
The completion of the purchase price to the seller of the SofPulse Technology (Had no choice or lose the assets and patent. The toxic noteholder has rights to the patent while ENDV needs to pay them back via dilution of common stock shares).
The new Roma medical device is on schedule for release in Q1 of 2019 (The release never happened)